Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 7/20 | 0.54 |
| ▸ | DRD5 | P21918 | 7/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18034983 | 0.95 | DRD1 (0.60) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL2056219 | 0.87 | DRD1 (0.55) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL2056215 | 0.83 | HTR2A (0.44) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL14048139 | 0.82 | DRD1 (0.44) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL13580305 | 0.80 | DRD2 (0.50) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL4317508 | 0.80 | DRD1 (0.79) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL29843474 | 0.80 | DRD1 (0.79) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL8118107 | 0.79 | EPHX2 (0.61) | — | |
| SCHEMBL2056218 | 0.79 | ALDH1A1 (0.47) | DRD1DRD5ALDH1A1SLC6A4HTR2A | |
| SCHEMBL7854911 | 0.78 | ESR1 (0.70) | HRH3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | DRD1 1062/4885DRD5 1204/4885DRD2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.